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Recent studies have showed that the bone marrow-derived endothelial progenitor cells play critical roles in metastasis and that ID1 is
required in metastasis as regulator of angiogenesis. Therefore, we investigated the clinical significance of ID1 mRNA expression in
bone marrow and peripheral samples in patients with gastric cancer. Two hundred and eighty-nine bone marrow and 196 peripheral
blood samples from gastric cancer patients were collected and analysed by quantitative RT–PCR for ID1. The ID1 protein expression
in one bone marrow, three metastatic lymph nodes and three peritoneal disseminated tumours was examined by
immunohistochemical methods. In both bone marrow and peripheral blood samples, ID1 mRNA expression in the metastatic
group was significantly higher than in any other group (P¼0.003, P¼0.0001, respectively) and significantly associated with lymph
node metastasis and peritoneal dissemination. The cells in bone marrow with metastatic cancer stained strongly with ID1 compared
with those of healthy volunteers. The expression of ID1 mRNA in bone marrow and peripheral blood was significantly associated
with lymph node metastasis and peritoneal dissemination, and therefore constitutes a predictable marker for lymph node metastasis
and peritoneal dissemination.
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The presence of isolated tumour cells (ITCs) is an important factor
in the metastasis of solid cancers. Recently, we investigated the
presence of ITCs in peripheral blood and in bone marrow, using
quantitative RT–PCR in more than 800 cases of gastric cancer
(Mimori et al, 2008). We found that ITCs circulate in a range of
clinical stages of gastric cancer. These data suggested that host
cells might play a supportive role for metastasis.
Recently, Kaplan et al reported that bone marrow-derived
haematopoietic progenitor cells that express vascular endothelial
growth factor receptor 1 (VEGFR-1) home to tumour-specific
pre-metastatic sites and form cellular clusters before the arrival
of tumour cells (Kaplan et al, 2005). In a large-scale study of
gastric cancer cases, we recently reported that the simultaneous
expression of ITC-associated genes and high levels of expression
of VEGFR-1 in bone marrow were significantly associated
with haematogeneous metastases (Mimori et al, 2008). Gao et al
determined that the bone marrow-derived endothelial progenitor
cells (EPCs) were critical regulators of angiogenic switching (Gao
et al, 2008). Furthermore, they showed that tumours induce
expression of ID1 in EPCs and that suppression of ID1 after
metastatic colonisation blocked EPC mobilisation, inhibited
angiogenesis and impaired pulmonary macrometastases. ID
proteins are inhibitors of DNA binding of basic helix-loop-helix
(bHLH) transcription factors by heterodimerisation with the
bHLH proteins (Benezra et al, 1990). ID1 has been reported to
be associated with the undifferentiation of cancer cells, severe
malignant grade of tumour, invasion of tumours and worse
prognosis in several tumours (Fong et al, 2003).
In this study, we investigated the clinical significance of the ID1
mRNA expression in bone marrow and peripheral blood samples
obtained from gastric cancer patients. The results showed that the
ID1 mRNA expression in bone marrow and peripheral blood was
significantly associated with lymph node metastasis and peritoneal
dissemination. Thus, ID1 is a bona fide predictive marker for both
pathologic parameters, each of which is an established definitive
prognostic indicator in gastric cancer.
MATERIALS AND METHODS
Patients
Physicians (TF and MS) collected bone marrow and peripheral
blood samples from 289 Japanese gastric cancer patients who
underwent surgery from 2001 to 2004 at the Central Hospital, the
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sNational Cancer Center, Tokyo, Japan. The documented informed
consent was obtained from all patients and the protocol of the
study was approved by the local ethics committee. There were 190
male and 99 female patients with an average age of 62.3 and a
range of 24–86 years (Table 1). Seventy of the patients showed
peritoneal dissemination at the time of surgery or at postoperative
follow-up. Among the 289 cases, 76, 60, 62 and 91 were classified as
stages I, II, III or IV, respectively, according to the Treaty for
Japanese Gastric Cancer Association (Maruyama et al, 2006).
Bone marrow and peripheral blood samples from gastric
cancer patients
Aspiration of both bone marrow and peripheral blood was
conducted under general anaesthesia immediately before surgery
as described earlier (Mimori et al, 2008). The bone marrow
aspirate was obtained from the sternum using a bone marrow
aspiration needle and peripheral blood was obtained through a
venous catheter. The first 1.0ml of bone marrow and peripheral
blood were discarded to avoid contamination by the skin. The
second collected 1.0ml of bone marrow and peripheral blood were
put into 4.0ml of Isogen-LS (Nippon Gene, Toyama, Japan) and
stored at  801C until RNA extraction.
Total RNA extraction and first-strand cDNA synthesis
Samples transferred from Tokyo to Beppu remained frozen while
in transit. Total RNA was extracted from bone marrow and
peripheral blood according to the manufacturer’s protocol as
described elsewhere (Iinuma et al, 2006). The reverse transcriptase
reaction (RT) was performed as described earlier (Mori et al,
1995). The first-strand cDNA was synthesised from 2.7mg of total
RNA in 30ml reaction mixtures containing 5ml5  RT buffer
(BRL, Gaithersburg, MD, USA), 200mM dNTP, a 100mM solution of
a random hexadeoxynucleotide mixture, 50 units of Rnasin
(Promega, Madison, WI, USA), 2ml of 0.1 M dithiothreitol and
100 units of Maloney leukemia virus RT (BRL). The mixture was
incubated at 371C for 60min, heated to 951C for 10min and then
chilled on ice.
Quantitative real-time RT–PCR
The sequences of ID1 mRNA were as follows: sense, 50-CC
AGTGGCAGCACCGCCACC-30, and anti-sense, 50-CGGATTCCG
AGTTCAGCTCC-30. We used glyceraldehyde-3-phosphate-dehy-
drogenase (GAPDH) as an internal control. The primers were as
follows: sense, 50-TTGGTATCGTGGAAGGACTCTA-30, and anti-
sense, 50-TGTCATATTTGGCAGGTT-30. Real-time monitoring of
PCR reactions was performed using the LightCycler system (Roche
Applied Science, Indianapolis, IN, USA) and SYBER-Green I dye
(Roche Diagnostics, Tokyo, Japan) to detect ID1 in bone marrow
and peripheral blood. Monitoring was performed according to the
manufacturer’s instructions, as described earlier (Ogawa et al,
2005). In brief, a master mixture was prepared on ice, containing
1ml of cDNA, 2ml of DNA Master SYBER-Green I mix, 50ng of
primers and 2.4mlo f2 5m M MgCl2. The final volume was adjusted
to 20ml with water. After the reaction mixture was loaded into glass
capillary tubes, quantitative RT–PCR was performed with the
following cycling conditions: initial denaturation at 951C for
10min, followed by 40 cycles of 951C for 10s, annealing at 621C for
10s and extension at 721C for 10s. After amplification, products
were subjected to a temperature gradient from 671Ct o9 5 1Ca t
0.21Cs
 1, under continuous fluorescence monitoring, to produce a
melting curve of products.
Table 1 Clinicopathlogial significance of ID1 mRNA expression in gastric cancer patients
Bone marrow Peripheral blood
Features Number
ID1 mRNA
expression (mean±s.d.) P-value Number
ID1 mRNA
expression (mean±s.d.) P-value
Age 289 62.3±11.9 — 196 62.9±12.2 —
Sex (M:F) 289 190:99 — 196 131:65 —
Tumour size 0.01 0.002
p5cm 126 311±146 85 24.8±12.2
X5cm 160 795±129 110 64.6±10.7
Depth of tumour invasion
a 0.01 0.004
m, sm 90 210±171 62 12.9±14.2
mp, ss, se, si 199 744±115 134 62.8±9.6
Venous invasion 0.97 0.007
Positive 72 580±199 50 77.8±15.2
Negative 188 571±123 128 28.9±9.5
Lymphatic invasion 0.001 0.02
Positive 156 850±132 110 57.8±10.3
Negative 104 158±162 68 18.2±13.1
Lymph node metastasis 0.001 0.02
Positive 188 800±121 132 56.7±9.6
Negative 79 58.7±186 50 12.4±15.6
Peritoneal dissemination
b 0.002 o0.0001
Positive 70 1102±194 40 119±17.1
Negative 218 412±110 156 28.6±8.6
aTumour invasion of mucosa (m), submucosa (sm), muscularis propria (mp), subserosa (ss), penetration of serosa (se) and invasion of adjacent strucures (si).
bPeritoneal
dissemination: peritoneal cytology or metastasis positive.
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We used the LightCycler Software version 3.5 program (Roche
Molecular Biochemicals, Basel, Switzerland) to calculate the cycle
numbers. After proportional baseline adjustment, a fit point
method was used to determine the cycle in which the log-linear
signal was first distinguishable from the baseline. This cycle
number was used as the crossing point value. A standard curve was
produced by measuring the crossing point of each standard value
and plotting it against the logarithmic value of the concentration.
Concentrations of unknown samples were calculated by plotting
their crossing points against the standard curve and dividing by
GAPDH content. The results of RT–PCR were sent from Beppu to
Tokyo for analyses.
Immunohistochemistry
Immunohistochemistry was performed on paraffin-embedded
specimens obtained from patients with metastatic gastric cancer
and two healthy volunteers. Tissue sections were deparaffinised,
soaked in 0.01 M sodium citrate buffer and boiled in a microwave
for 5min at 500W to retrieve cell antigens. The primary rabbit
polyclonal antibody against ID1 (C-20; Santa Cruz Biotechnology,
Santa Cruz, CA, USA), which detects ID1 in paraffin-embedded
human tissue sections and does not crossreact with ID2, ID3 or
ID4 (Maruyama et al, 1999), was used at a dilution of 1:100. The
blocking peptide to ID1 (sc-488P, Santa Cruz Biotechnology) was
used as a negative control (Supplementary Figure 4). Tissue
sections were immunohistochemically stained using the avidin–
biotin-peroxidase method (LSABþ system-HRP; DAKO, Kyoto,
Japan). All sections were counterstained with haematoxylin.
Statistical analysis
The expression of ID1 was adjusted in each case for GAPDH
expression. For continuous variables, data were expressed as the
means±s.d. The relationship between ID1 mRNA expression and
clinicopathlogical factors was analysed using a w
2 test and
Student’s t-test. All tests were analysed using JMP software (SAS
Institute Inc., Cary, NC, USA) and the findings were considered
significant when the P-value was o0.05.
RESULTS
Expression of ID1 mRNA in bone marrow of gastric cancer
Figure 1A shows expression of ID1 mRNA in bone marrow
according to staging classification. In bone marrow, the mean
expression level of ID1 mRNA in stage IV (957±169) was
significantly higher than other stages (P¼0.003). Specifically, the
levels of stages I, II and III were 54±185, 472±208, and 767±205,
respectively. To confirm the specificity of ID1, we performed
RT–PCR analysis of six representative cases in each stage, which
was very close to the average value (Figure 1C). In addition,
sequencing of these transcripts confirmed that it was the product
of ID1 (Supplementary Figure 1).
Expression of ID1 mRNA in peripheral blood of gastric
cancer
In the peripheral blood samples, there was a significant relation-
ship between the expression level of ID1 mRNA and the
progression of gastric cancer cases (Figure 1B). The mean
expression level of ID1 mRNA in stage IV (105±15) was
significantly higher (P¼0.0001) than stages I, II and III
(12.4±15.4, 29.6±15.5, and 38.3±16.0, respectively). In addition,
there was a significant correlation between the expression of ID1
mRNA in bone marrow and peripheral blood (r¼0.23, P¼0.002,
data not shown).
ID1 expression and clinicopathological features of gastric
cancer patients
We examined the clinicopathlogical significance of ID1 mRNA in
samples from bone marrow and peripheral blood (Table 1). In
both bone marrow and peripheral blood, there are significant
associations with many cliniopathlogical features such as tumour
size and depth of tumour invasion. Especially, in patients with
evidence of lymphatic invasion, lymph node metastasis or
peritoneal dissemination, we found significantly higher expression
of ID1 mRNA in bone marrow samples compared to patients
without metastasis. (P¼0.001, P¼0.001 and P¼0.002, respec-
tively, Figures 2A–C). Similarly, in peripheral blood samples, the
cases with lymphatic invasion, lymph node metastasis or
peritoneal dissemination had significantly higher expression of
ID1 mRNA compared to patients without metastasis. (P¼0.02,
P¼0.02 and Po0.0001 respectively, Figures 3A–C).
Expression of ID1 protein in bone marrow from patients
with metastatic gastric cancer and healthy volunteers
The ID1 protein expression in bone marrow was evaluated
immunohistochemically in studies of metastatic gastric cancer
patients and healthy volunteers. In bone marrow of healthy
volunteer (Figure 4A), the ID1 expression was localised mainly in
the nuclei of bone marrow cells. The population of ID1-positive
cells in healthy volunteer is lower than that in metastatic patient
(Figure 4B). The ID1 expression of bone marrow cells with
metastatic patient was also localised mainly in the nuclei. We also
examined the ID1 expression of bone marrow carcinomatosis
resulting from gastric cancer. The metastasized cancer cells were
confirmed to be epithelial cells by HE (Supplementary Figure 2A)
stain and AE1/AE3 (Supplementary Figure 2B). These cells were
stained slightly with ID1 antibody in the cytoplasm (Figure 4C).
ID1 expression in primary lesions and metastatic lesions of
gastric cancer
We examined the ID1 protein expression immunohistochemically
in 30 primary lesions, 3 metastatic lymph nodes and 3 peritoneal
disseminated lesions of gastric cancer cases. We found that 20
cases have high ID1 expression in primary lesions (Figure 5A).
Some of the cases showed weak (Supplementary Figure 3A) or
moderate (Supplementary Figure 3B) ID1 staining. In addition,
two of three metastatic lymph nodes and peritoneal disseminated
lesions were stained slightly with the ID1 antibody and the ID1
expression was localised in the cytoplasm of cancer cells in
primary lesion, metastatic lymph node metastasis and peritoneal
dissemination (Figures 5B and C).
DISCUSSION
Peritoneal dissemination is recognised as the most critical factor in
assessing the prognosis of gastric cancer cases (Bando et al, 1999).
There is no conclusive evidence, however, whether peritoneal
dissemination might be established by the lymph node metastasis
as well as direct dissemination from the serosal layer of stomach
(Yonemura et al, 2007). In this study, the ID1 mRNA expression in
bone marrow and peripheral blood was significantly associated
with lymph node metastasis and peritoneal dissemination. There-
fore, we suggest that peritoneal dissemination of gastric cancer is
mediated through lymph node metastasis combined with the
ID1-expressing endothelial cells from bone marrow. From a
clinical point of view, there are no convincing markers for
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speritoneal dissemination before surgery. Therefore, it is significant
that the ID1 expression in bone marrow and peripheral blood can
be used as a reliable marker before surgery to determine which
gastric cancer patients are likely to have peritoneal dissemination
mediated through lymph node metastasis.
There are two possible sources of the ID1-positive cells: ITC and
host cells (such as EPCs, as stated by Gao et al). With regard to
tumour cells, Tsuchiya et al showed that the number and size of
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Figure 1 The mean value of ID1 mRNA expression normalised GAPDH in bone marrow (A) and peripheral blood (B) according to staging classification.
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lower; GAPDH product size 270bp).
0
200
400
600
800
1000
1200
ly(+) ly(–)
0
200
400
600
800
1000
1200
1400
N(+)
I
D
1
/
G
A
P
D
H
 
(
B
M
)
P=0.001 P=0.001
P=0.002
0
200
400
600
800
1000
1200
1400
cy or P(+)
I
D
1
/
G
A
P
D
H
 
(
B
M
)
I
D
1
/
G
A
P
D
H
 
(
B
M
)
n=156 n=104
n=70 n=218
n=188
N(–)
n=79
cy and P(–)
Figure 2 Comparison of the ID1 mRNA expression in bone marrow of
patients with or without lymphatic invasion (ly) (þ: n¼156,  : n¼ 104; A),
lymph node metastasis (N)( þ: n¼188,  : n¼ 79; B) and peritoneal
cytology (cy) or peritoneal metastasis (P) (þ: n¼70;  : n¼ 218; C). In
patients with evidence of lymphatic invasion, lymph node metastasis or
peritoneal dissemination, the expression of ID1 mRNA in bone marrow was
significantly higher compared to patients without metastasis.
P<0.0001
0
20
40
60
80
100
120
140
160
cy or P(+)
P=0.02 P=0.02
0
10
20
30
40
50
60
70
80
ly(+) ly(–)
0
10
20
30
40
50
60
70
80
N(+) N(–)
I
D
1
/
G
A
P
D
H
 
(
P
B
)
 
I
D
1
/
G
A
P
D
H
 
(
P
B
)
 
I
D
1
/
G
A
P
D
H
 
(
P
B
)
 
n=110 n=68
n=40 n=156
n=132 n=50
cy and P(–)
Figure 3 Comparison of the ID1 mRNA expression in peripheral blood of
patients with or without lymphatic invasion (ly) (þ: n¼110,  : n¼68; A),
lymph node metastasis (N) (þ: n¼132, -: n¼ 50; B) and peritoneal
cytology (cy) or peritoneal metastasis (P) (þ: n¼40,  : n¼156; C). In
patients with evidence of lymphatic invasion, lymph node metastasis or
peritoneal dissemination, the expression of ID1 mRNA in peripheral blood
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speritoneal metastatic nodules formed by ID1 and ID3 double-
knockdown gastric cancer cells were reduced in comparison to
mock-transfected control cells in vivo (Tsuchiya et al, 2005).
Furthermore, Kim et al reported that transgenic mice expressing a
thymocyte-specific Id1 gene developed T-cell lymphoma in vivo
(Kim et al, 1999). In addition, overexpression of ID1 in the
primary cancer cells relative to normal mucosa has been observed
in primary human oesophageal (Hu et al, 2001) and colorectal
cancers (Wilson et al, 2001). Those reports found that the ID1
expression was significantly associated with the differentiation of
AB
C
Figure 4 Immunohistochemistry with ID1 antibody, assessing bone marrow from a representative healthy volunteer and metastatic gastric cancer patient.
In the bone marrow of healthy volunteer (A), the ID1 expression was localised mainly in the nuclei of bone marrow cells. The population of ID1-positive
cells in healthy volunteer is lower than that in metastatic patients (B). The metastasized cells confirmed to be epithelial cells by HE stain and AE1/AE3
(Supplementary Figures 2A and B) that originated from gastric cancer were stained slightly with ID1 in cytoplasm (C). (A–C: original magnification: 100).
A B
C
Figure 5 Immunohistochemistry with ID1 antibody assessing primary and metastatic lesions. Most of the primary lesions of gastric cancer were stained
strongly with the ID1 antibody. A representative case was shown in (A). The ID1 expression was localised in the cytoplasm of cancer cells in primary lesion,
metastatic lymph node metastasis (B) and peritoneal dissemination (C). (Original magnification: A:  40, B and C:  100).
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scells and a poor prognosis. In gastric cancer, Han et al found that
strong immunohistochemical ID1 expression was associated with
poorer differentiation and more aggressive behaviour of tumour
cells (Han et al, 2004). In this study, we also examined the ID1
expression in primary lesion of gastric cancer cases. We found that
two-thirds cases have high ID1 expression in primary lesions
(Figure 5A). Furthermore, we showed that the metastasized cancer
cells from gastric cancer in bone marrow were slightly stained with
ID1 antibody (Figure 4C). These findings suggest that ID1 may be a
potential oncogene. As for the origin of ID1-positive cells in bone
marrow, these seem to represent ITCs.
On the other hand, in this study, we present two lines of
evidence indicating that the origin of the ID1 expression is from
host cells, perhaps originating from bone marrow or peripheral
blood. First, immunohistochemical studies showed that the
population of ID1-positive cells in healthy volunteer is lower than
that in metastatic patients (Figure 4A). Thus, ID1-expressing cells
are particularly numerous in the bone marrow in which there are
relatively few cancer cells. The current findings may suggest that
ID1 is not a component of the aggregated cancer cells in the
metastatic lymph nodes and peritoneal disseminated tumours, but
instead plays a supportive role for gastric cancer cells to form
lymph node metastasis and peritoneal dissemination.
Secondary, Gao et al found that Id1 was expressed by EPC positive
for VE-cadherin and CD31 in peripheral blood (Gao et al, 2008).
As we expected, the ID1 expression in peripheral blood was
significantly related to the incidence of peritoneal dissemination.
In addition, there were significant association between ID1 expres-
sion in peripheral blood and those in bone marrow from gastric
cancer cases. This finding may indicate that the expression of ID1 in
peripheral blood originates from the circulating progenitor cells
(CPCs), including EPC and from the bone marrow (Lyden et al,
2001). Those results may suggest that the origin of ID1 expression is
not only from cancer cells but also from host cells, such as CPCs in
bone marrow and peripheral blood.
In summary, we found that the ID1 mRNA expression in bone
marrow and peripheral blood is a reliable predictive marker for
lymph node metastasis and peritoneal dissemination, which
indicates a poor prognostic outlook in gastric cancer. In addition,
our findings suggest that the ID1 expression originates from not
only the cancer cells but also the host side progenitor cells with the
cancer-bearing condition. Therefore, we propose that targeting the
ID1-expressing cells in the bone marrow and/or peripheral blood
after surgery represents a new concept for the treatment and/or
prevention of metastasis.
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